Remzistotug

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Antibody
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Antibody
www.ebi.ac.uk
Drug name
Remzistotug
www.ebi.ac.uk

  • gsk 4381562
  • GSK 4381562 [WHO-DD]
  • gsk 4381562 who dd
  • gsk 4381562a
  • GSK-4381562
  • GSK-4381562A
  • gsk4381562
  • GSK4381562
  • gsk4381562a
  • GSK4381562A
  • h gamma1 heavy chain homo sapiens 1 453 vh homo sapiens ighv1 69 10 95 9 ighd ighj5 02 100 cdr imgt 8 8 16 26 33 51 58 97 112 1 123 homo sapiens ighg1 01 100 g1m17 1 ch1 k120 ch3 d12 l14 ch1 k120 220 124 221 hinge 1 15 222 236 ch2 237 346 ch3 d12 362 l14 364 347 451 chs 452 453 124 453 226 213 disulfide with l kappa light chain homo sapiens 1 213 v kappa homo sapiens igkv1 39 01 100 igkj4 01 100 cdr imgt 6 3 8 27 32 50 52 89 96 1 106 homo sapiens igkc 01 100 km3 a45 1 v101 c kappa a45 1 152 v101 190 107 213 dimer 232 232 235 235 bisdisulfide produced in chinese hamster ovary cho cells cell line cho k1 glycoform alfa
  • H-gamma1 heavy chain Homo sapiens (1-453) [VH (Homo sapiens IGHV1-69*10 (95.9%) -(IGHD) -IGHJ5*02 (100%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123) -Homo sapiens IGHG1*01 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (220) (124-221), hinge 1-15 (222-236), CH2 (237-346), CH3 D12 (362), L14 (364) (347-451), CHS (452-453)) (124-453)], (226-213')-disulfide with L-kappa light chain Homo sapiens (1'-213') [V-KAPPA (Homo sapiens IGKV1-39*01 (100%) -IGKJ4*01 (100%), CDR-IMGT [6.3.8] (27'-32'.50'-52'.89'-96')) (1'-106') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (152'), V101 (190')) (107'-213')]; dimer (232-232'':235-235'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa
  • immunoglobulin g1 anti human transmembrane protein pvrig human monoclonal gsk4381562a γ1 chain disulfide with human monoclonal gsk4381562a κ chain dimer
  • immunoglobulin g1 kappa anti homo sapiens pvrig poliovirus receptor pvr related immunoglobulin domain containing nectin2 receptor cd112 receptor cd112r homo sapiens monoclonal antibody
  • immunoglobulin G1-kappa, anti-[Homo sapiens PVRIG (poliovirus receptor (PVR) related immunoglobulin domain containing, NECTIN2 receptor, CD112 receptor, CD112R)], Homo sapiens monoclonal antibody
  • Immunoglobulin G1, anti-(human transmembrane protein PVRIG) (human monoclonal GSK4381562A γ1-chain), disulfide with human monoclonal GSK4381562A κ-chain, dimer
  • remzistotug
  • Remzistotug
  • remzistotug [INN]
  • REMZISTOTUG [USAN]
  • remzistotug inn
  • remzistotug usan
  • srf 813
  • SRF-813
  • srf813

And 1 more, listed on the interactive page.

CAS registry numbers
  • 2920425-39-2
ChEMBL ID
CHEMBL6068072
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • 4U47PC3GYR

First in class
No
Orphan designation
No

Investigated indications

  • Condition
    Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000616
    Subject identifier
    D009369

  • Condition identifier
    EFO_0000616
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0005070
  • Condition identifier
    MONDO_0010150
    Highest recorded phase
    2

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Heavy chain
    Type
    Protein
    Sequence
    QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSAAISWVRQAPGQGLEWMGNIIPIVGIANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDTGRGYTRHFWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  • Component
    Disulfide bridges
    Sequence
    22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 133'-193' $ 133'''-193''' $ 150-206 $ 150''-206'' $ 226-213' $ 226''-213''' $ 232-232'' $ 235-235'' $ 267-327 $ 267''-327'' $ 373-431 $ 373''-431''
  • Component
    Light chain
    Type
    Protein
    Sequence
    DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSDILYTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
  • Component
    Glycosylation sites (N)
    Sequence
    303 $ 303''

Related records

Trials (2)

In development for (1)